$OTS Holdings (OTS.SG)$ bottom line better but please do something with your top line.
$Suntec Reit (T82U.SG)$ sgd 2.1 now. Wait long long for Tang as offer is grossly unattractive.
ref
1. Gordon Tang Sweetens Suntec REIT Bid as Investors Shun Offer - Mingtiandi
2. Suntec Reit unitholders should reject revised S$1.19-a-unit offer: Morningstar
ref
1. Gordon Tang Sweetens Suntec REIT Bid as Investors Shun Offer - Mingtiandi
2. Suntec Reit unitholders should reject revised S$1.19-a-unit offer: Morningstar
2
4
$Olam Group (VC2.SG)$ 1.13 on paying $3.5 mil to CFTC. Ref: Olam agrees to pay US$3.3 mil in settlement with Commodity Futures Trading Commission
1
1
$Tesla (TSLA.US)$ usd220.110. Cited production challenge for the unique design, may take time to reach cash flow positive for Cybertruck, and faced challenges and delays since 2019.
Reference
1. https://www.businessinsider.com/elon-musk-says-cybertruck-faces-enormous-production-challenges-tesla-2023-10
Reference
1. https://www.businessinsider.com/elon-musk-says-cybertruck-faces-enormous-production-challenges-tesla-2023-10
1
2
$Pacific Biosciences of California (PACB.US)$ usd 8.04. it was unfortunate that PacBio could not move to profit since 2007. The only time it got surplus was the payment by Illumina for the terminated merger. Sigh.
1
$Pfizer (PFE.US)$ usd 38.30. Pfizer's lotiglipron dropped, danuglipron still in the test pipeline for obesity drug. Alternative includes Novo Nordisk's Ozempic which is also at mid-stage testing (ref. 1).
Ref
1. https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-discontinue-development-obesity-drug-2023-06-26/
Ref
1. https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-discontinue-development-obesity-drug-2023-06-26/
$BioNTech (BNTX.US)$ usd 126.58 2023 sales expected to be lower due to tapering demand for Covid-19 vaccine (ref fiercepharma.com). several lawsuits: This year, Arbutus Biopharma to file patent lawsuit against Pfizer & BioNTech over Covid vaccines (ref. Reuter). In 2022, Moderna and Alnylam respectively sued Pfizer/BioNTech for patent infringement. Any good news? Jan 2023 BioNTech partnered with UK Government to provide patients with personalised mRNA cancer immunotherapies by 203...
$Suntec Reit (T82U.SG)$ sgd 1.34. Concern about tech sector slowdown (constituting approx 40% its leasee), high interest rate, high gearing (i.e., debt-to-equity), 30% lease due for renewal. Good points is high occupancy, long-term leases, forex hedged . Strategy anticipated: divest assets to lower debt (ref. 1)
reference
1. https://www.theedgesingapore.com/capital/brokers-calls/rhb-downgrades-suntec-reit-neutral-lower-tp-147
reference
1. https://www.theedgesingapore.com/capital/brokers-calls/rhb-downgrades-suntec-reit-neutral-lower-tp-147
2
$Top Glove (BVA.SG)$ sgd 0.215. It is time to reduce the expenses. If covid-driven scaled-up production and its related cost is not permanent, we are safe, else it will be very bad. This is in consideration of the current challenges, i.e., over-supply, increased competition, raw material price hike (e.g., latex, crude oil), minimum wage increase in Malaysia in 2022, and others.
The extraordinary demand may had been du...
The extraordinary demand may had been du...